BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 25919767)

  • 1. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages contribute to cellular but not humoral mechanisms of acute rejection in rat renal allografts.
    Ma FY; Woodman N; Mulley WR; Kanellis J; Nikolic-Paterson DJ
    Transplantation; 2013 Dec; 96(11):949-57. PubMed ID: 24056626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
    Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
    Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Model of Acute Antibody-Mediated Renal Allograft Rejection in the Sensitized Rata.
    Chandran SR; Mulley WR; Kanellis J; Nikolic-Paterson DJ; Ma FY
    Exp Clin Transplant; 2018 Jun; 16(3):294-300. PubMed ID: 28760115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.
    Halloran PF; Reeve JP; Pereira AB; Hidalgo LG; Famulski KS
    Kidney Int; 2014 Feb; 85(2):258-64. PubMed ID: 23965521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor-based therapy for antibody-mediated rejection.
    Walsh RC; Alloway RR; Girnita AL; Woodle ES
    Kidney Int; 2012 Jun; 81(11):1067-74. PubMed ID: 22336990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide prolongs pulmonary allograft and xenograft survival.
    Yuh DD; Gandy KL; Morris RE; Hoyt G; Gutierrez J; Reitz BA; Robbins RC
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1136-44. PubMed ID: 8719461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short course of cyclosporine immunosuppression inhibits rejection but not tolerance of rat liver allografts.
    Huang WH; Yan Y; De Boer B; Bishop GA; House AK
    Transplantation; 2003 Feb; 75(3):368-74. PubMed ID: 12589161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
    Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
    Trials; 2014 Dec; 15():489. PubMed ID: 25494823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological risks of minimization strategies.
    Snanoudj R; Tinel C; Legendre C
    Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model.
    Kubo K; Kawato Y; Nakamura K; Nakajima Y; Nakagawa TY; Hanaoka K; Oshima S; Fukahori H; Inami M; Morokata T; Higashi Y
    Eur J Pharmacol; 2018 Nov; 838():145-152. PubMed ID: 30196110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
    Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
    Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
    Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
    Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.